Parkinson's Disease News
-
TV viewers will be forgiven if they feel a sense of deja vu when new shows debut in September. With competition from cable and the Web growing, broadcasters are leaning more on past successes and big names to find fresh hits.
-
Almost five years after Lehman Brothers Holding Inc. filed for bankruptcy and set off the global financial crisis, managers of the bank’s estate are demanding millions of dollars from retirement homes, colleges and hospitals.
-
Michael J. Fox left prime-time television more than a decade ago to focus on his battle with Parkinson’s disease. Now he’s back, with the help of drugs that keep his own shaking from the illness mostly under control.
-
Comcast Corp.’s NBC is going back to the future to refresh its Thursday night lineup, anchored by a new comedy starring Michael J. Fox.
-
A Medtronic Inc. device used to stimulate the brain to treat Parkinson’s disease and other neurological conditions has a potentially life-threatening flaw that triggered the highest-level warning from U.S. regulators.
-
A Manhattan co-op that belonged to Arthur O. Sulzberger, the former publisher of the New York Times who died in September, sold for $12.5 million.
-
Orion Oyj, a Finnish drugmaker, climbed to its highest in almost four weeks after SEB AB said potential partnership deals could double cash flow this year.
-
Acadia Pharmaceuticals Inc., a biotechnology company with $5 million in annual revenue, surged to its highest value in five years after saying it will gain a U.S. regulatory review of its lead drug sooner than anticipated.
-
Patients with early Parkinson’s disease who respond to drug therapy gain improvement in their symptoms and quality of life when they receive deep-brain stimulation from an implanted medical device, a study showed.
-
One of the most promising new approaches to treating Parkinson’s disease hit a snag after researchers found early evidence it may make people worse.
|
|
Parkinson's Disease Photos
Most Popular on Bloomberg
|
|
Parkinson's Disease Videos
|
|
Rate this Page